Brooklyn ImmunoTherapeutics, Inc. (BTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.7455 |
| Open | 0.7699 |
| Bid | 0.6705 x 1300 |
| Ask | 0.6800 x 800 |
| Day's Range | 0.6701 - 0.7778 |
| 52 Week Range | 0.5900 - 23.3400 |
| Volume | |
| Avg. Volume | 483,030 |
| Market Cap | 35.015M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4470 |
| Earnings Date | Mar 09, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.50 |
- GlobeNewswire
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q
SAN DIEGO, May 27, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that it received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”), stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ende
- GlobeNewswire
Amarin Announces Appointment of New Directors and Board Leadership Changes
Erin Enright and Alfonso “Chito” Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company’s Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Board’s Commitment to Ongoing Refreshment and Enhancement DUBLIN, Ireland and BRIDGEWATER, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a series of appointments and leader
- GlobeNewswire
Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines
Company has expanded team with scientific hires who hold research expertise in stem cells, synthetic RNA, nanoparticle delivery systems and immunologySAN DIEGO, April 21, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the establishment
